Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Zealand Pharma AS's current 5-Year Share Buyback Ratio was -13.60%.
ZLDPY's 5-Year Share Buyback Ratio is ranked worse than 57.89% of 1121
companies
in the Biotechnology industry
Industry Median: -10.2
vs ZLDPY: -13.60
Zealand Pharma AS (OTCPK:ZLDPY) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Zealand Pharma AS 5-Year Share Buyback Ratio Related Terms
ZLDPY vs VRTX, REGN, MRNA: 5-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Zealand Pharma AS's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS 5-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's 5-Year Share Buyback Ratio falls into.
Zealand Pharma AS 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -13.60 mean?
Zealand Pharma AS (ZLDPY) has a 5-Year Share Buyback Ratio of -13.60 as of Jun. 2017. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #649 out of 1121 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Zealand Pharma AS's 5-Year Share Buyback Ratio too high?
Zealand Pharma AS's current 5-Year Share Buyback Ratio is -13.60. Based on the distribution chart, Zealand Pharma AS ranks #649 out of 1121 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zealand Pharma AS has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's 5-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #649 out of 1121 companies for 5-Year Share Buyback Ratio. This places Zealand Pharma AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Biotechnology company?
A good 5-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Zealand Pharma AS and its competitors. Zealand Pharma AS's current 5-Year Share Buyback Ratio is -13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPY) is currently considered Possible Value Trap. The stock's GF Value™ is $358.32, compared to a current price of $8.67 — trading 97.6% below its estimated fair value. The current 5-Year Share Buyback Ratio is -13.60. Zealand Pharma AS's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPY), the current 5-Year Share Buyback Ratio is -13.60 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPY) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $8.67 is trading 97.6% below its estimated GF Value™ of $358.32.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPY:
5-Year Share Buyback Ratio: -13.60
GF Value™: $358.32 vs. price of $8.67 (97.6% below fair value)
No single metric tells the full story. See the ZLDPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma A/S is a Danish biotechnology company that discovers, designs, and develops peptide-based medicines, primarily for metabolic and gastrointestinal diseases. Its pipeline includes dasiglucagon, a glucagon analog approved as Zegalogue for severe hypoglycemia and developed for congenital hyperinsulinism and bihormonal artificial pancreas systems; glepaglutide for short bowel syndrome; and survodutide, a dual GLP-1/glucagon receptor agonist licensed to Boehringer Ingelheim for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. The company also has partnered programs with other pharmaceutical companies, generating revenue through licensing fees, milestone payments, and royalties. Zealand Pharma is headquartered in Copenhagen, Denmark, and is listed on Nasdaq Copenhagen and, through American Depositary Receipts, on Nasdaq in the United States. Its customers and collaborators are primarily large pharmaceutical companies and healthcare providers in Europe, North America, and other developed markets.
42GF Score
Get the complete analysis for ZLDPY
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPY has been successfully added to your 
